P3781
Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 PatientsActive Surveillance Research Program for the Assessment of the Safety and the Effectiveness of LinagliptinA Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy VolunteersEfficacy vs Placebo as Initial Combination Therapy With PioglitazoneLinagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 DiabetesThe Effect of Linagliptin on Mitochondrial and Endothelial FunctionA Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database AnalysesEfficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.Efficacy and Safety of Empagliflozin in NODATA Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is InappropriateSafety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DMEffect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes MellitusPharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /MetforminEfficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes PatientsFinding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 DiabetesCAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 DiabetesThis Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate PillsEffect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal InsufficiencyRotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin TherapyEffect of Linagliptin + Metformin vs Metformin Alone in Patients With PrediabetesRenal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetESComparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin TabletA Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy VolunteersEfficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin TherapyEfficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic ControlDiabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TMDIA_CENTRAL:T2D Treatment Pattern in Central EuropeA Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyReal World Glycemic Effectiveness of LinagliptinEffect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes MellitusSafety Evaluation of Adverse Reactions in DiabetesBioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy SubjectsBioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes MellitusA Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)ADA Linagliptin in Long Term Care
P4844
Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetesLinagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesityLinagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjecSafety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.Clinical pharmacokinetics and pharmacodynamics of linagliptin.The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.Efficacy and safety of linagliptin (tradjenta) in adults with type-2 diabetes mellitus.Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.Pharmacokinetics of linagliptin in subjects with hepatic impairmentLinagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled studyDesign, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.Linagliptin: in type 2 diabetes mellitus.Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor.Review of linagliptin for the treatment of type 2 diabetes mellitus.Linagliptin: a review of its use in the management of type 2 diabetes mellitus.The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers.Vilazodone hydrochloride, linagliptin, and alcaftadine.Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats.Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin.Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients.The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.
P921
Q61713093-D67B2D92-6ABC-4CF8-BF02-5CEE9E63ED11Q61864727-6739D72B-46F6-4E69-9405-6B6AF68491C4Q61906974-B3D03144-B333-47FD-812E-78AE09F291BDQ61914863-FFBE2E1B-1B4C-4B5D-8F73-3B94CB5612EDQ61955741-58D5B19F-E0E8-481A-B659-2759C35BAA3BQ61975462-DF003017-A64E-432B-AFBC-62D33DA220F7Q61975544-DE158364-8737-4017-8B68-28407B7C7590Q62025587-A742394A-8128-403B-A235-D87861BA8A3EQ62031688-7E35783C-43D3-42CB-AD26-7DD3C32F71D4Q62062802-10885F1C-7291-47E0-AD45-DE0391B8B377Q63062858-DB997929-4AE1-4817-B6D3-E50E214C8583Q63063362-44819F07-62FB-4555-AF0A-EE78EBE0A352Q63316773-C93D4ED4-90D0-4BBC-8972-730318CF49CCQ63319193-35DD1E21-A261-4B8E-AFBB-E01027889A55Q63321810-27A266B7-9AFE-4552-B86C-6C0AFC5E1B15Q63337539-F35E73ED-F028-4482-8A2C-4B0A66586B7BQ63340041-FB3AFB0B-8CBA-4BBC-98EB-39AB53EC2DA1Q63393203-58C29AD4-54A5-44AF-A7DD-8C0B6EE171F3Q63393231-AE626B50-4DA0-44CF-9F80-CDBE91C51B9BQ63397949-3955210C-0140-44C0-9269-A4896BABC79EQ63534957-74492830-59AA-4926-9666-D621003F4C35Q63573977-1652AD0B-2F8E-45E0-90F6-FBEBA42CF35FQ63613547-1D9C943C-9E7C-4121-A9A2-A7C66EF279C7Q63811734-F07676F9-0DB7-4CD1-91FB-006EEAC58367Q63811878-E3DA92E7-66FB-488B-ABB7-FC8166EA7E8BQ63818461-623501F2-FBD2-470F-8EAC-B445A7C3A574Q63818669-F03D4F0B-B074-4832-8126-61F433175348Q63818795-D26D815C-36BB-436C-82EA-4D049D4D6D24Q64139385-39FCD1E8-14D8-49ED-B8C1-23452A29C77FQ64139934-3589337A-5A63-471D-9101-D09BEE0B8B03Q64186739-7B4D6B97-65F3-4D53-9062-FDA37CD5C7B8Q64187582-B5A6500F-6E90-49C8-A9D7-4D9B77C780A8Q64187826-307B4CF6-EC62-46EC-BBC4-611870506C6EQ64220151-8574D0B3-4115-4CAD-B689-8A26CA58E459Q64220519-F95479C4-7D30-44E6-A441-6592C15E3A4BQ64221576-977269F8-6727-4C02-9939-9665F590EE37Q64221578-F68AD1D3-E838-4C3A-9D5C-B3982617989BQ64222085-B8322D54-BE67-4DB4-95C6-9B988156309CQ64222583-7ED77C72-6CA8-4B7C-8B2B-82D16AA40518Q64223360-6D3C0BE5-F1B0-4366-9CE1-B26C15264CFB
P4844
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische stof
@nl
name
Linagliptin
@de
Linagliptin
@vi
linagliptin
@en
linagliptin
@hu
linagliptin
@it
linagliptin
@nn
linagliptin
@sh
linagliptin
@sr
linagliptina
@es
linagliptine
@fr
type
label
Linagliptin
@de
Linagliptin
@vi
linagliptin
@en
linagliptin
@hu
linagliptin
@it
linagliptin
@nn
linagliptin
@sh
linagliptin
@sr
linagliptina
@es
linagliptine
@fr
altLabel
(R)-8-(3-aminopiperidin-1-yl)- ...... )-3,7-dihydro-purine-2,6-dione
@en
BI 1356
@en
BI-1356
@en
Tradjenta®
@en
Trajenta
@de
тражента
@ru
prefLabel
Linagliptin
@de
Linagliptin
@vi
linagliptin
@en
linagliptin
@hu
linagliptin
@it
linagliptin
@nn
linagliptin
@sh
linagliptin
@sr
linagliptina
@es
linagliptine
@fr